A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder
Introduction: Darifenacin and trospium are the commonly used antimuscarinics in the management of overactive bladder (OAB). Constipation is the second most common treatment related sideeffect. Though its incidence with the above two medications is known, data on their comparative severity and imp...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2015-03-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/5677/11884_CE(RA1)_F(T)_PF1(PAK)_PFA(AK)_PF2(PAG)_u.pdf |
| Summary: | Introduction: Darifenacin and trospium are the commonly used
antimuscarinics in the management of overactive bladder (OAB).
Constipation is the second most common treatment related sideeffect. Though its incidence with the above two medications is
known, data on their comparative severity and impact on patient’s
well-being is lacking.
Materials and Methods: Sixty subjects with OAB included in the
study were randomized in 1:1 fashion to receive either darifenacin
7.5 mg OD or trospium extended release 60 mg OD. Treatment
response was monitored using overactive bladder symptom
score (OABSS). The severity of constipation was assessed using
McMillan & Williams Constipation assessment scale (CAS), Bristol
stool form scale and Knowles-Eccersley-Scott-Symptom (KESS)
questionnaire score administered at baseline, 2 and 4 weeks of
treatment.
Results: OABSS improved significantly, -5.80 ± 3.99 (p = 0.0005)
and -5.27 ± 2.98 (p = 0.0005) in darifenacin and trospium groups
respectively. However, the difference between the two groups
was not significant either at 2 weeks (p = 0.952) or 4 weeks (p =
0.654) of treatment. A significant decrease in stool consistency
was noted with darifenacin treatment (p < 0.05), but the same
was not seen with trospium (p = 0.076). There was no significant
difference in scores of KESS questionnaire between baseline,
2 weeks and 4 weeks, both within the group and between the
groups (p > 0.05). McMillan & Williams CAS scores increased
at week 2 and week 4, in comparison with baseline scores in
both darifenacin and trospium treated patients, however, the
difference between the two groups was not statistically significant
(p > 0.05).
Conclusion: Darifenacin and trospium are equally efficacious and
comparable in tolerability in terms of constipation severity and its
impact on patient well-being. |
|---|---|
| ISSN: | 2249-782X 0973-709X |